The calculation of RRs for the pooled adverse events showed that GH therapy was associated with a statistically significant reduction in the risk of worsening HF (RR = 0.52; 95% CI, 0.29-0.91; P = .025) and the composite outcome of death, worsening HF failure, or VT (RR = 0.59; 95% CI, 0.39-0.90; P = .013) compared to placebo. The gene discussed is GH1; the disease is hydrops fetalis.